Abstracts tagged "dendritic cells and interferons"

Abstract Number: 2092 • 2018 ACR/ARHP Annual Meeting
Glucocorticoid-Induced Leucine Zipper (GILZ) Is a Novel Checkpoint Regulator of Type I Interferon (IFN) Production in SLE
Champa Nataraja¹, Eric Morand¹, Jacinta Lee¹, Taylah Bennett¹, Jacqueline Flynn¹, James Harris¹ and Sarah Jones², ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Glucocorticoids (GC) remain the frontline treatment in Systemic Lupus Erythematosus (SLE) despite their predictable metabolic adverse effects. Type I interferons (IFN), produced by TLR7…
Abstract Number: 2885 • 2016 ACR/ARHP Annual Meeting
Expression Levels and Function of the Inhibitory Molecule, Immunoglobulin like Transcript 7 (ILT7), Are Decreased on Circulating Plasmacytoid Dendritic Cells in SLE Patients with High ANA Titers
Mark A. Jensen¹, Jessica M. Dorschner², Danielle Vsetecka², Shreyasee Amin³, Ashima Makol³, Floranne C. Ernste⁴, Thomas Osborn³, Kevin Moder³, Vaidehi Chowdhary³ and Timothy B. Niewold⁵, ¹Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁵Rheumatology and Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disease often involving multiple organs. In SLE, immune complexes containing autoreactive antibody and nuclear material activate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].